MX356813B - Derivados de hidantoina utiles como inhibidores de kv3. - Google Patents

Derivados de hidantoina utiles como inhibidores de kv3.

Info

Publication number
MX356813B
MX356813B MX2014006753A MX2014006753A MX356813B MX 356813 B MX356813 B MX 356813B MX 2014006753 A MX2014006753 A MX 2014006753A MX 2014006753 A MX2014006753 A MX 2014006753A MX 356813 B MX356813 B MX 356813B
Authority
MX
Mexico
Prior art keywords
inhibitors
derivatives useful
hydantoin derivatives
hydantoin
compounds
Prior art date
Application number
MX2014006753A
Other languages
English (en)
Other versions
MX2014006753A (es
Inventor
Giuseppe Alvaro
Agostino Marasco
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2011/052414 external-priority patent/WO2012076877A1/en
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Publication of MX2014006753A publication Critical patent/MX2014006753A/es
Publication of MX356813B publication Critical patent/MX356813B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)

Abstract

La invención proporciona compuestos de fórmula (I): (ver Fórmula) dichos compuestos son moduladores de canales Kv3 y de uso en la profilaxis o tratamiento de trastornos relacionados.
MX2014006753A 2011-12-06 2012-12-06 Derivados de hidantoina utiles como inhibidores de kv3. MX356813B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2011/052414 WO2012076877A1 (en) 2010-12-06 2011-12-06 Hydantoin derivatives useful as kv3 inhibitors
PCT/GB2012/053045 WO2013083994A1 (en) 2011-12-06 2012-12-06 Hydantoin derivatives useful as kv3 inhibitors

Publications (2)

Publication Number Publication Date
MX2014006753A MX2014006753A (es) 2014-10-15
MX356813B true MX356813B (es) 2018-06-13

Family

ID=47429936

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006753A MX356813B (es) 2011-12-06 2012-12-06 Derivados de hidantoina utiles como inhibidores de kv3.

Country Status (14)

Country Link
EP (1) EP2788339B1 (es)
JP (1) JP5985651B2 (es)
KR (1) KR20140098850A (es)
CN (1) CN103974944B (es)
AU (1) AU2012349847B2 (es)
CA (1) CA2856654C (es)
DK (1) DK2788339T3 (es)
ES (1) ES2576628T3 (es)
HK (1) HK1203072A1 (es)
IL (2) IL232612B (es)
IN (1) IN2014CN04014A (es)
MX (1) MX356813B (es)
PL (1) PL2788339T3 (es)
WO (1) WO2013083994A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
EP2852588B8 (en) 2012-05-22 2018-01-10 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
CN104334547B (zh) 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
WO2013182851A1 (en) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
WO2018220762A1 (ja) * 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
WO2019222816A1 (en) 2018-09-21 2019-11-28 Bionomics Limited Substituted-pyridinyl compounds and uses thereof
TWI827706B (zh) * 2018-10-16 2024-01-01 英商奧堤凡尼治療股份有限公司 新穎化合物
BR112022013339A2 (pt) 2020-02-06 2022-09-13 Autifony Therapeutics Ltd Moduladores de kv3
IL310160A (en) 2021-08-10 2024-03-01 Autifony Therapeutics Ltd potassium channel modulators
WO2024121552A1 (en) 2022-12-06 2024-06-13 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders
CN117448440A (zh) * 2023-10-23 2024-01-26 中国人民解放军空军军医大学 Kv3在制备诊断或治疗创伤后应激障碍异常恐惧记忆消退产品中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675403A (en) * 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
DK123493D0 (da) * 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
CN102256968A (zh) * 2008-12-22 2011-11-23 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
ES2575215T3 (es) * 2009-12-11 2016-06-27 Autifony Therapeutics Limited Derivados de imidazolidindiona
KR20120104343A (ko) * 2009-12-14 2012-09-20 에프. 호프만-라 로슈 아게 헤테로환형 항바이러스성 화합물
DK2649066T3 (en) * 2010-12-06 2016-01-11 Autifony Therapeutics Ltd Hydantoin derivatives using as KV3 inhibitors.
US9193704B2 (en) * 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors

Also Published As

Publication number Publication date
JP2015502951A (ja) 2015-01-29
IL258704A (en) 2018-06-28
PL2788339T3 (pl) 2016-09-30
IL232612A0 (en) 2014-06-30
EP2788339A1 (en) 2014-10-15
CN103974944A (zh) 2014-08-06
CA2856654A1 (en) 2013-06-13
MX2014006753A (es) 2014-10-15
HK1203072A1 (zh) 2015-10-16
KR20140098850A (ko) 2014-08-08
CN103974944B (zh) 2016-11-02
CA2856654C (en) 2020-03-31
DK2788339T3 (en) 2016-05-23
ES2576628T3 (es) 2016-07-08
EP2788339B1 (en) 2016-03-09
AU2012349847A1 (en) 2014-06-26
IL232612B (en) 2018-07-31
AU2012349847B2 (en) 2017-02-16
IN2014CN04014A (es) 2015-07-10
WO2013083994A1 (en) 2013-06-13
IL258704B (en) 2019-05-30
JP5985651B2 (ja) 2016-09-06

Similar Documents

Publication Publication Date Title
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
MX356813B (es) Derivados de hidantoina utiles como inhibidores de kv3.
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
IN2015DN01156A (es)
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
PH12015500525A1 (en) Formulations of enzalutamide
MX368833B (es) Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor.
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
MX354988B (es) Formulaciones de anticuerpo y metodos.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
CA2887539C (en) Azaquinazoline carboxamide derivatives
MX348397B (es) Uso de extractos de filipendula para el tratamiento y profilaxis de dolor crónico.
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
IN2014DN00254A (es)
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
MX2011013324A (es) Uso de derivados de oxindol sustituidos para el tratamiento y profilaxis del dolor.
IN2015DN02109A (es)
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
EA201270727A1 (ru) Пуриновые соединения

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration